Ivailo Alexiev1, Anupama Shankar2, A M J Wensing3, Danail Beshkov4, Ivaylo Elenkov5, Mariyana Stoycheva6, Daniela Nikolova7, Maria Nikolova8, William M Switzer2. 1. National Reference Laboratory of HIV, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria ivoalexiev@yahoo.com. 2. Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA. 3. University Medical Center Utrecht, Virology, Utrecht, The Netherlands. 4. National Reference Laboratory of HIV, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria. 5. Hospital for Infectious and Parasitic Diseases, Sofia, Bulgaria. 6. Department of Infectious Diseases, Medical University, Plovdiv, Bulgaria. 7. Clinic of Infectious Diseases, Medical University, Varna, Bulgaria. 8. National Reference Laboratory of Immunology, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.
Abstract
OBJECTIVES: To determine transmitted drug resistance (TDR) and HIV-1 genetic diversity in Bulgaria. METHODS: The prevalence of TDR and HIV-1 subtypes was determined in 305/1446 (21.1%) persons newly diagnosed with HIV/AIDS from 1988 to 2011. TDR mutations (TDRMs) in protease and reverse transcriptase were defined using the WHO HIV drug mutation list. Phylogenetic analysis was used to infer polymerase (pol) genotype. RESULTS: TDRMs were found in 16/305 (5.2%) persons, 11 (3.6%) with resistance to NRTIs, 5 (1.6%) with resistance to NNRTIs and 3 (0.9%) with resistance to PIs. Dual-class TDRMs were found in three (1.0%) patients and one statistically supported cluster of TDRMs comprising two individuals with subtype B infection. TDRMs were found in 10 heterosexuals, 4 MSM and two intravenous drug users. Phylogenetic analyses identified high HIV-1 diversity consisting of mostly subtype B (44.6%), subtype C (3.3%), sub-subtype A1 (2.6%), sub-subtype F1 (2.3%), sub-subtype A-like (3.6%), subtype G (0.3%), CRF14_BG (1.6%), CRF05_DF (1.3%), CRF03_AB (0.3%) and unique recombinant forms (1.3%). CONCLUSIONS: We found a low prevalence of TDR against a background of high HIV-1 genetic diversity among antiretroviral-naive patients in Bulgaria. Our results provide baseline data on TDR and support continued surveillance of high-risk populations in Bulgaria to better target treatment and prevention efforts.
OBJECTIVES: To determine transmitted drug resistance (TDR) and HIV-1 genetic diversity in Bulgaria. METHODS: The prevalence of TDR and HIV-1 subtypes was determined in 305/1446 (21.1%) persons newly diagnosed with HIV/AIDS from 1988 to 2011. TDR mutations (TDRMs) in protease and reverse transcriptase were defined using the WHO HIV drug mutation list. Phylogenetic analysis was used to infer polymerase (pol) genotype. RESULTS: TDRMs were found in 16/305 (5.2%) persons, 11 (3.6%) with resistance to NRTIs, 5 (1.6%) with resistance to NNRTIs and 3 (0.9%) with resistance to PIs. Dual-class TDRMs were found in three (1.0%) patients and one statistically supported cluster of TDRMs comprising two individuals with subtype B infection. TDRMs were found in 10 heterosexuals, 4 MSM and two intravenous drug users. Phylogenetic analyses identified high HIV-1 diversity consisting of mostly subtype B (44.6%), subtype C (3.3%), sub-subtype A1 (2.6%), sub-subtype F1 (2.3%), sub-subtype A-like (3.6%), subtype G (0.3%), CRF14_BG (1.6%), CRF05_DF (1.3%), CRF03_AB (0.3%) and unique recombinant forms (1.3%). CONCLUSIONS: We found a low prevalence of TDR against a background of high HIV-1 genetic diversity among antiretroviral-naive patients in Bulgaria. Our results provide baseline data on TDR and support continued surveillance of high-risk populations in Bulgaria to better target treatment and prevention efforts.
Authors: Santiago Pérez-Parra; Natalia Chueca; Marta Álvarez; Juan Pasquau; Mohamed Omar; Antonio Collado; David Vinuesa; Ana Belen Lozano; Gonzalo Yebra; Federico García Journal: PLoS One Date: 2017-10-30 Impact factor: 3.240
Authors: Maja M Lunar; Snježana Židovec Lepej; Janez Tomažič; Tomaž D Vovko; Blaž Pečavar; Gabriele Turel; Manja Maver; Mario Poljak Journal: PLoS One Date: 2018-04-26 Impact factor: 3.240
Authors: Ivailo Alexiev; Ellsworth M Campbell; Sergey Knyazev; Yi Pan; Lyubomira Grigorova; Reneta Dimitrova; Aleksandra Partsuneva; Anna Gancheva; Asya Kostadinova; Carole Seguin-Devaux; William M Switzer Journal: Viruses Date: 2020-04-14 Impact factor: 5.048
Authors: Maja Oroz; Josip Begovac; Ana Planinić; Filip Rokić; Maja M Lunar; Tomaž Mark Zorec; Robert Beluzić; Petra Korać; Oliver Vugrek; Mario Poljak; Snježana Židovec Lepej Journal: Sci Rep Date: 2019-11-21 Impact factor: 4.379